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HUGO Statement on Pharmacogenomics (PGx): Solidarity, Equity 
and Governance 
 
HUMAN GENOME ORGANISATION ETHICS COMMITTEE 
 
Reason for Statement 
 
The HUGO Ethics Committee, 
 
• Recognising that there have been significant discussions of the ethical issues 
arising in the application of genetic knowledge;1 
• Recognising that PGx has the potential to maximize therapeutic outcomes and 
minimize adverse reactions to therapy, and that it is consistent with the traditional 
goals of public health and medical care to relieve human suffering and save lives; 
• Recognising that the ethical, research and policy issues that need to be considered 
in PGx include: 
o the ways in which PGx requires a novel focus on families, populations and 
communities; 
o the impact of ‘personalised’ medicine on a society; 
o the implications for populations in developing countries, including access to 
therapies for neglected diseases; 
o the impact of PGx on health care costs and policies worldwide; 
o the significance of PGx for research priorities;  
o the importance of re-evaluation of prior clinical trial data for efficacy among 
particular genotypes (as in resuscitation of abandoned drugs); 
o the significance of PGx for existing, as opposed to new, drugs; and 
o the fear that PGx could reinforce genetic determinism and lead to 
discrimination against, and stigmatization of, individuals and groups; 
 
hereby identifies a pressing need to reach consensus on the most important ethical 
principles that are applicable and for workable guidelines in clinical and public health 
settings. 
 
Definitions and scope 
 
There has been extensive discussion of the relative benefits of using the terms 
pharmacogenomics (PGx) and pharmacogenetics, and various definitions have been 
suggested. To some extent the terms have been used interchangeably. Although both 
‘genetics’ and ‘genomics’ are popularly used in different ways in different cultures, 
and have different meanings in a variety of languages, in this statement we use the 
term pharmacogenomics (PGx) and understand ‘PGx’ to mean the total sum of genetic 
variation that affects response to therapeutic agents. 
 
The Committee recognises that principles developed in this Statement on PGx also 
apply to other therapeutic modalities such as ionising radiation and biologicals, and to 
variation in response in contexts such as nutrition, environmental exposures and 
toxicology. 
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Principles 
 
Past HUGO Ethics Committee Statements have reflected a commitment to the view 
that the highest ethical priority in implementing genomic knowledge is that of saving 
life and reducing suffering, but the Committee considers it urgent that the ethical 
principles of solidarity and equity be given increased attention 
 
• Solidarity: Because of shared vulnerabilities, people have common interests and 
moral responsibilities to each other. Willingness to share information and to 
participate in research is a praiseworthy contribution to society. 
• Equity: To reduce health inequalities between different populations, and to work 
towards equal access to care is an important prerequisite for implementing 
genomic knowledge for the benefit of society. 
 
while also reaffirming the following long-accepted ethical considerations: 
 
• Respect for human rights 
• Protection of confidentiality and privacy 
• Avoiding harm 
• Beneficence: there is an obligation to do good, and to maximise the possible 
benefits of genomics, which should be regarded as a global public good 
• Autonomy: the freedom of persons to make decisions regarding their medical care 
is fundamental to the modern practice of medicine 
• The authority of communities to participate in decisions that affect them 





1. Research priorities 
 
1.1. There needs to be a careful consideration of research priorities in PGx and 
translational research for each society and these should not merely be led by 
economic priorities determined by market forces. 
1.2. The continuing creation of a sound scientific basis for PGx should be pursued, 
such as: 
identification of genetic factors, including genes, haplotypes, SNPs and 
copy number variants (CNVs) with significant pharmacogenomic effects; 
identification of interactions with other genetic, environmental and social 
factors among drugs currently in common use in different countries; meta-
analyses for consistency of data; ongoing development of methods for bio-
marker analyses that are suitable for large scale studies. 
1.3. The continuing creation of a sound corpus of research on ethical and legal 
issues, appropriate governance, social science and policy research, and 
methods of community and public dialogue and participation. 
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2. Governance of research 
 
2.1. There needs to be appropriate governance at national and international levels 
of the collection, storage, utilization, sharing, and protection of data and 
biological specimens.  
2.2. There is an urgent need for institutions and scientists to apply the principle of 
open access and sharing of data, consistent with the protection of personal 
privacy of the persons contributing to the database, in order to maximise 
benefit. 
2.3. The establishment of necessary infrastructure, including international 
initiatives for sharing data between biobanks, should be supported. 
2.4. There should be support and encouragement by research funding agencies to 
require and support the sharing of data. 
2.5. HUGO should consider establishing mechanisms for on-going international 
co-ordination and evaluation of developments in PGx, with special reference 
to harmonising standards for reliability and replicability of PGx association 
studies. 
2.6. While many institutions have developed governance mechanisms, such as 
ethics committees, attention should be paid to preparing them to assess 
appropriately the benefits and risks of PGx protocols. 
 
3. Maximising the benefits of research 
 
3.1. It should be recognised that PGx can be of benefit to communities as well as to 
individuals, even in the absence of optimal infrastructure/resources 
3.2. In order to reduce health inequalities, there is a need both to develop new 
drugs for people with certain genetic variants, especially in the case of 
neglected and orphan diseases, and to consider the possibility of resuscitation 
of abandoned drugs for particular population groups. 
 
4. Participation in research and social responsibility 
 
4.1. All stakeholders in PGx research should exercise their ethical responsibilities 
in a spirit of equity and solidarity. 
4.2. Voluntary participation of members of a community in PGx research provides 
an opportunity to actualise the principle of solidarity. Researchers have an 
obligation to engage the community while maintaining the highest standard of 
research conduct to earn the trust of the community. 
4.3. The participation of all stakeholders, including the wider community, in such 
research requires public and professional dialogue and education in the science 
and ethics of PGx. 
 
5. Clinical implementation 
  
5.1. The principle of equity implies that therapies should be made equally available 
to those with equal needs. If this were not the case, the translation of genomic 
knowledge into clinical practice would aggravate disparities among people. 
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5.2. Barriers to translation of genomic knowledge into practice should be identified 
and addressed, e.g., by training of appropriate personnel; by working towards 
more equitable health care systems; etc. 
5.3. An individual’s serious side effect, or absence of response, may have 
important implications for drug treatment of blood relatives. The unit of care 
with respect to drug treatment may include the family as well as the 
individual, e.g., physicians should be alert to the implications for the relatives 
of a patient who suffers a serious adverse drug reaction, and should initiate 
genetic counselling. 
5.4. Voluntary sharing of PGx information within families should be encouraged. 
 
6. Monitoring and quality control 
 
6.1. There needs to be agreement upon a standard set of data to be collected and a 
common format to facilitate international data sharing. 
6.2. Systematic recording of clinical drug reactions to obtain data useful for PGx 
research should be encouraged. 
6.3. Robust mechanisms of quality control need to be in place to minimise the 
possibility of error in individual PGx testing and maintenance of patient 
records. 
6.4. Regulatory agencies should address the implications of PGx practice on a wide 
scale, including the possibilities of off-label use and liability issues. 
 
7. Education, training and awareness 
 
7.1. In the light of the rapid growth in PGx knowledge there is an urgent need to 
increase the level of awareness, education and training in the above issues for 
all stakeholders, including researchers, clinicians, policy makers, social 
scientists, patients and publics. 
 
The HUGO Ethics Committee 
 
Professor Kåre Berg (Vice Chair), Norway; Professor Ruth F. Chadwick (Chair), 
UK; Professor Jose Maria Cantu, Mexico; Professor Abdallah S. Daar, Oman and 
Canada; Professor Kazuto Kato, Japan; Professor Darryl R. J. Macer, New 
Zealand and Thailand; Professor John J. Mulvihill, USA; Professor Thomas H. 
Murray, USA; Professor Carlos M. Romeo-Casabona, Spain; Professor Ishwar 
Verma (Vice Chair), India; Professor Zhai Xiaomei, China 
 
Montreal, May 2007 
 
                                                 
1 The Universal Declaration on Bioethics and Human Rights was unanimously adopted on 19 October 
2005 by all member countries of UNESCO. It follows two specific Declarations on ethics of 
applications of genomics that all member countries of UNESCO have agreed to; the Universal 
Declaration on the Human Genome and Human Rights (1997), also adopted unanimously by all UN 
members in 1998, and the International Declaration on Human Genetic Data (2003). In addition there 
have been many declarations and scholarly articles, and proclamations by agencies and committees of 
national governments, which provide insight into the theoretical issues and practical applications of 
ethics to issues raised by genomics, that we draw upon herein. 
